Zosano Pharma Corp (NASDAQ:ZSAN) has been assigned a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company. Zosano Pharma Corp’s rating score has improved by 16.5% in the last 90 days as a result of various analysts’ ratings changes.
Brokers have set a 1 year consensus price objective of $5.42 for the company and are anticipating that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Zosano Pharma Corp an industry rank of 97 out of 265 based on the ratings given to related companies.
ZSAN has been the subject of several research reports. Zacks Investment Research lowered shares of Zosano Pharma Corp from a “buy” rating to a “hold” rating in a research note on Wednesday, January 18th. Roth Capital set a $3.00 price target on shares of Zosano Pharma Corp and gave the stock a “buy” rating in a research note on Tuesday, February 14th. Finally, Piper Jaffray Companies began coverage on shares of Zosano Pharma Corp in a research note on Friday, March 24th. They issued an “overweight” rating and a $4.00 price target for the company.
Shares of Zosano Pharma Corp (NASDAQ:ZSAN) traded down 1.667% during trading on Monday, reaching $1.475. 220,361 shares of the company were exchanged. The stock’s market capitalization is $28.69 million. Zosano Pharma Corp has a one year low of $0.45 and a one year high of $3.54. The stock has a 50-day moving average price of $1.87 and a 200-day moving average price of $1.25.
Zosano Pharma Corp (NASDAQ:ZSAN) last issued its quarterly earnings results on Wednesday, March 1st. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.01. Analysts forecast that Zosano Pharma Corp will post ($0.87) EPS for the current year.
In related news, major shareholder Enterprise Associates 12 New sold 1,099,996 shares of the stock in a transaction dated Monday, February 13th. The shares were sold at an average price of $2.01, for a total transaction of $2,210,991.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.37% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ZSAN. Armistice Capital LLC increased its stake in shares of Zosano Pharma Corp by 43.2% in the fourth quarter. Armistice Capital LLC now owns 1,200,000 shares of the biotechnology company’s stock valued at $936,000 after buying an additional 362,000 shares during the period. Hudson Bay Capital Management LP purchased a new stake in shares of Zosano Pharma Corp during the third quarter valued at approximately $186,000. Finally, Lombard Odier Asset Management USA Corp increased its stake in shares of Zosano Pharma Corp by 66.7% in the third quarter. Lombard Odier Asset Management USA Corp now owns 795,722 shares of the biotechnology company’s stock valued at $615,000 after buying an additional 318,450 shares during the period. 41.11% of the stock is currently owned by institutional investors.
Zosano Pharma Corp Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.